182 related articles for article (PubMed ID: 38662587)
1. Response Evaluation Criteria in Gastrointestinal and Abdominal Cancers: Which to Use and How to Measure.
Castagnoli F; Mencel J; Ap Dafydd D; Gough J; Drake B; Mcaddy NC; Withey SJ; Riddell AM; Koh DM; Shur JD
Radiographics; 2024 May; 44(5):e230047. PubMed ID: 38662587
[TBL] [Abstract][Full Text] [Related]
2. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
Wahl RL; Jacene H; Kasamon Y; Lodge MA
J Nucl Med; 2009 May; 50 Suppl 1(Suppl 1):122S-50S. PubMed ID: 19403881
[TBL] [Abstract][Full Text] [Related]
3. The Tipping Point: Key Oncologic Imaging Findings Resulting in Critical Changes in the Management of Malignant Tumors of the Gastrointestinal Tract.
Wu J; Goyal L; Nipp R; Wo J; Qadan M; Uppot RN
Curr Probl Diagn Radiol; 2019 Jan; 48(1):61-74. PubMed ID: 29674013
[TBL] [Abstract][Full Text] [Related]
4. Decoding Genes: Current Update on Radiogenomics of Select Abdominal Malignancies.
Katabathina VS; Marji H; Khanna L; Ramani N; Yedururi S; Dasyam A; Menias CO; Prasad SR
Radiographics; 2020 Oct; 40(6):1600-1626. PubMed ID: 33001791
[TBL] [Abstract][Full Text] [Related]
5. Imaging of Gastrointestinal Stromal Tumors: From Diagnosis to Evaluation of Therapeutic Response.
Vernuccio F; Taibbi A; Picone D; LA Grutta L; Midiri M; Lagalla R; Lo Re G; Bartolotta TV
Anticancer Res; 2016 Jun; 36(6):2639-48. PubMed ID: 27272772
[TBL] [Abstract][Full Text] [Related]
6. The Interaction of Genomics, Molecular Imaging, and Therapy in Gastrointestinal Tumors.
Wahl RL
Semin Nucl Med; 2020 Sep; 50(5):471-483. PubMed ID: 32768010
[TBL] [Abstract][Full Text] [Related]
7. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group.
Kalkmann J; Zeile M; Antoch G; Berger F; Diederich S; Dinter D; Fink C; Janka R; Stattaus J;
Cancer Imaging; 2012 May; 12(1):126-35. PubMed ID: 22572545
[TBL] [Abstract][Full Text] [Related]
8. PET/MR Imaging in Cancers of the Gastrointestinal Tract.
Paspulati RM; Gupta A
PET Clin; 2016 Oct; 11(4):403-23. PubMed ID: 27593246
[TBL] [Abstract][Full Text] [Related]
9. Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art.
de Mestier L; Dromain C; d'Assignies G; Scoazec JY; Lassau N; Lebtahi R; Brixi H; Mitry E; Guimbaud R; Courbon F; d'Herbomez M; Cadiot G
Endocr Relat Cancer; 2014 Jun; 21(3):R105-20. PubMed ID: 24351682
[TBL] [Abstract][Full Text] [Related]
10. Fetal intra-abdominal tumors: assessment of spectrum, accuracy of prenatal diagnosis, perinatal outcome and therapy at a tertiary referral center.
Amari F; Beyer DA; Diedrich K; Weichert J
Eur J Obstet Gynecol Reprod Biol; 2013 Apr; 167(2):160-6. PubMed ID: 23295072
[TBL] [Abstract][Full Text] [Related]
11. Radiological evaluation of the therapeutic response of malignant diseases: status quo, innovative developments and requirements for radiology.
Höink AJ; Heindel W; Buerke B
Rofo; 2014 Oct; 186(10):927-36. PubMed ID: 25122173
[TBL] [Abstract][Full Text] [Related]
12. Non Size Based Morphology Criteria for Assessment of Response in Patients with Liver Metastases of Gastrointestinal Origin Receiving Systemic Treatment.
Alhanafy A; Abdullah MS; Hafez H; Abbas H
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1655-1660. PubMed ID: 29938450
[TBL] [Abstract][Full Text] [Related]
13. Role of radiomics in the diagnosis and treatment of gastrointestinal cancer.
Mao Q; Zhou MT; Zhao ZP; Liu N; Yang L; Zhang XM
World J Gastroenterol; 2022 Nov; 28(42):6002-6016. PubMed ID: 36405385
[TBL] [Abstract][Full Text] [Related]
14. Personalized Clinical Decision Making in Gastrointestinal Malignancies: The Role of PET.
Hess S; Bjerring OS; Pfeiffer P; Høilund-Carlsen PF
PET Clin; 2016 Jul; 11(3):273-83. PubMed ID: 27321031
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead.
Sundin A; Rockall A
Neuroendocrinology; 2012; 96(4):261-71. PubMed ID: 22907438
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in Gastrointestinal Malignancies.
Surana R; Pant S
Adv Exp Med Biol; 2021; 1342():259-272. PubMed ID: 34972968
[TBL] [Abstract][Full Text] [Related]
17. Advances in oncological treatment: limitations of RECIST 1.1 criteria.
Grimaldi S; Terroir M; Caramella C
Q J Nucl Med Mol Imaging; 2018 Jun; 62(2):129-139. PubMed ID: 29166754
[TBL] [Abstract][Full Text] [Related]
18. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.
Liapi E; Geschwind JF; Vossen JA; Buijs M; Georgiades CS; Bluemke DA; Kamel IR
AJR Am J Roentgenol; 2008 Jan; 190(1):67-73. PubMed ID: 18094295
[TBL] [Abstract][Full Text] [Related]
19. Imaging for Staging of Pediatric Abdominal Tumors: An Update, From the
Morin CE; Artunduaga M; Schooler GR; Brennan RC; Khanna G
AJR Am J Roentgenol; 2021 Oct; 217(4):786-799. PubMed ID: 33825502
[TBL] [Abstract][Full Text] [Related]
20. Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival.
Xie P; Zheng H; Chen H; Wei K; Pan X; Xu Q; Wang Y; Tang C; Gevaert O; Meng X
BMC Cancer; 2021 Nov; 21(1):1246. PubMed ID: 34798858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
